ARTICLE | Deals
Ono’s $2.4B Deciphera buy adds two cancer therapies, grows U.S. presence
With end of Opdivo’s exclusivity on the horizon, Japanese pharma continues to take steps in global expansion
April 29, 2024 7:56 PM UTC
With its planned $2.4 billion acquisition of Deciphera, Japanese pharma Ono would gain two oncology therapies — one approved, one on the brink of FDA submission — while also deepening its presence in the U.S. as part of a global expansion.
Ono Pharmaceutical Co. Ltd. (Tokyo:4528) proposed to pay $25.60 per share to acquire Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH). The price represents a 75% premium over Friday’s close...